CD19 and plasma cell myeloma: In both patients, the percentage of myeloma cells on which we detected CD19 by dSTORM was higher compared to FC: in patient M012 this were 68% by dSTORM vs. 30.4% by FC, and in patient M016 this were 32% by dSTORM vs. 4.9% by FC (Fig. 2b and Table 1).